C4 Therapeutics, Inc.

NASDAQ:CCCC

3.87 (USD) • At close December 24, 2024
Bedrijfsnaam C4 Therapeutics, Inc.
Symbool CCCC
Munteenheid USD
Prijs 3.87
Beurswaarde 273,179,430
Dividendpercentage 0%
52-weken bereik 3.61 - 11.88
Industrie Biotechnology
Sector Healthcare
CEO Mr. Andrew J. Hirsch M.B.A.
Website https://www.c4therapeutics.com

An error occurred while fetching data.

Over C4 Therapeutics, Inc.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple

Vergelijkbare Aandelen

OraSure Technologies, Inc. logo

OraSure Technologies, Inc.

OSUR

3.69 USD

EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc.

EYPT

7.33 USD

ALX Oncology Holdings Inc. logo

ALX Oncology Holdings Inc.

ALXO

1.83 USD

Absci Corporation logo

Absci Corporation

ABSI

3.01 USD

HilleVax, Inc. logo

HilleVax, Inc.

HLVX

1.87 USD

Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc.

HRTX

1.58 USD

BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc.

BTAI

0.351 USD

Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc.

FULC

4.55 USD

Anika Therapeutics, Inc. logo

Anika Therapeutics, Inc.

ANIK

16.33 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)